Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FBPZE
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $39,045
Award facts
- Contract value 100% obligated
- $39,045.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $39,045.44 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The delivery order, issued on December 10, 2025, with an ultimate completion date of December 11, 2025, was executed without a set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group will perform the work at its Park Ridge facility and will serve as the sole contractor with no identified subcontractor relationships on this award.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was established on November 13, 2025, with a $499.999 billion ceiling value extending through December 31, 2036. The PPV-G GEN V represents a $30.3 billion federal acquisition strategy designed to provide recurring pharmaceutical and medical supply needs to military healthcare facilities worldwide. Through this comprehensive contract vehicle, DMS Pharmaceutical Group has demonstrated substantial performance capacity across a diverse portfolio encompassing branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals to support Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FBPZE?
SPE2DR26FBPZE was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 10, 2025.
How much is contract SPE2DR26FBPZE worth?
The government has obligated $39,045 on SPE2DR26FBPZE.
Is contract SPE2DR26FBPZE an order under another contract?
Yes. SPE2DR26FBPZE is a delivery order under SPE2DR25D9304, an indefinite delivery contract.
Was contract SPE2DR26FBPZE competed?
The extent of competition for SPE2DR26FBPZE was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award